Children's Mercy Kansas City

SHARE @ Children's Mercy
Posters
11-2022

Malignancy masquerading as steroid resistant hypereosinophilic
syndrome
Sonya Parashar
Aarti Pandya

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/posters
Part of the Allergy and Immunology Commons

Hypereosinophilia with an anterior mediastinal mass (9153)
1,2
MD ;

1,2
MD

Sonya Parashar
Aarti Pandya
1Children’s Mercy Kansas City 2University of Missouri Kansas City

Background
• HES characterized by blood eosinophilia
of 1500 EOS/mL with evidence of endorgan damage attributable to
eosinophilia and no other cause.
• Rare in adults but even more rare in
children
• Causes are divided between primary or
clonal versus secondary or non-clonal
including allergic disease, infections,
drug reactions

Case presentation
• A 3-year-old male with questionable history
of asthma was admitted for newly found
anterior mediastinal mass and left pleural
effusion.
• Past surgical history: none.
• Family history: no family history of
eosinophilic disorders.
• Medications: albuterol, Flovent
• CT chest showed large left pleural effusion,
possible abscess, small pericardial effusion,
and concern for an anterior mediastinal mass
due to mediastinal shift.

Case presentation continued

Management

• The patient’s absolute eosinophil count suddenly increased from 600 to 25,048 and remained
elevated above 20,000.
• He developed recurrent eosinophilic pericardial effusions requiring multiple
pericardiocentesis.
• Despite high dose steroids and inpatient use of mepolizumab, his hypereosinophilia persisted.
• After two inconclusive fine-needle aspirations of his mediastinal mass, the patient’s family
agreed to a sternotomy with removal of the mediastinal mass.
• Pathology eventually revealed myeloid sarcoma, a variant of acute myeloid leukemia.

• High-dose steroids in 1 mg/kg/day in children and
adults
• Patients with MHES and LHES are least responsive
to corticosteroids
• For those with FIP1L1-PDGFRA gene, imatinib is
effective.
• Mepolizumab approved for 12 years old and
greater with dose of 300 mg every 4 weeks
particularly in patients who were FIP1L1-PDGFRA
negative.

Figure 1: Coronal view of mass

Figure 2: Axial view of mass with neon green lines

Conclusions
• Since HES is so rare, mainly case reports are
available.
• Steroid resistant HES should raise concern for
underlying malignancy especially when
eosinophils are above 20,000.
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